14.09.2014 Views

BEVACIZUMAB EFFECT ON TOPOTECAN PHARMACOKINETICS ...

BEVACIZUMAB EFFECT ON TOPOTECAN PHARMACOKINETICS ...

BEVACIZUMAB EFFECT ON TOPOTECAN PHARMACOKINETICS ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Eq. 6<br />

<br />

Eq. 7<br />

The variables X1, X2, X3, X4, X5 and X6 are to the drug amounts in the central,<br />

absorption, peripheral, two transient compartments and tumor compartments; Ke is<br />

systemic elimination rate constant; Kcp and Kpc are intercompartment rate constants<br />

between peripheral and central compartments; Kct is elimination rate constant from<br />

central compartment to tumor compartment; Kte is elimination rate constant leaving from<br />

tumor compartment; Vc is volume of distribution in central compartment and Vt is<br />

volume of distribution in tumor compartment.<br />

2.2.8 Population pharmacokinetic analysis<br />

Non linear mixed effects modeling using the MLEM algorithm implemented in<br />

ADAPT 5 [181] was used to evaluate the TPT plasma and tumor ECF concentrations. In<br />

the MLEM algorithm, ML is combined with an EM algorithm. The EM algorithm<br />

consists of two steps. In the first step, each individual’s parameters are estimated using<br />

the latest predicted parameter values and the observed data. In the second step, parameter<br />

values are updated to maximize the log-likelihood function in the first step. These two<br />

steps are then iterated until convergence. The initial values for population means and<br />

population covariance matrix (inter-individual variability) were estimated by naïve<br />

pooled analysis. Both population and individual estimates ware determined. The<br />

model-fitted curve for each mouse was used to estimate the area under the<br />

concentration-time curve from time zero to 6 hr in plasma (AUCp) and tumor ECF<br />

(AUCt). The measures of penetration were expressed as AUC tumor-to-plasma ratio<br />

(AUCt/AUCp).<br />

2.2.9 Covariate analysis<br />

A diagnostic screening was done to identify covariates such as the presence of<br />

BEV in the treatment and the different schedules of the combination therapy that<br />

potentially affected TPT PK parameters, including systemic elimination rate Ke,<br />

elimination rate from tumor compartment Kte and volume of distribution in tumor<br />

compartment Vt. These potential covariates were then included in the non-linear<br />

mixed-effects population model to investigate their ability to significantly improve the<br />

model fit (by a reduction of at least 3.84 [p

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!